Literature DB >> 28843668

Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections.

Bruce R Levin1, Fernando Baquero2, Peter Pierre Ankomah3, Ingrid C McCall4.   

Abstract

Most antibiotic use in humans is to reduce the magnitude and term of morbidity of acute, community-acquired infections in immune competent patients, rather than to save lives. Thanks to phagocytic leucocytes and other host defenses, the vast majority of these infections are self-limiting. Nevertheless, there has been a negligible amount of consideration of the contribution of phagocytosis and other host defenses in the research for, and the design of, antibiotic treatment regimens, which hyper-emphasizes antibiotics as if they were the sole mechanism responsible for the clearance of infections. Here, we critically review this approach and its limitations. With the aid of a heuristic mathematical model, we postulate that if the rate of phagocytosis is great enough, for acute, normally self-limiting infections, then (i) antibiotics with different pharmacodynamic properties would be similarly effective, (ii) low doses of antibiotics can be as effective as high doses, and (iii) neither phenotypic nor inherited antibiotic resistance generated during therapy are likely to lead to treatment failure.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28843668     DOI: 10.1016/j.tim.2017.07.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  15 in total

Review 1.  Antimicrobial resistance: new insights and therapeutic implications.

Authors:  Bashir Ahmad Sheikh; Basharat Ahmad Bhat; Manzoor Ahmad Mir
Journal:  Appl Microbiol Biotechnol       Date:  2022-09-19       Impact factor: 5.560

2.  Effect of drug dose and timing of treatment on the emergence of drug resistance in vivo in a malaria model.

Authors:  Mónica M Acosta; Joshua T Bram; Derek Sim; Andrew F Read
Journal:  Evol Med Public Health       Date:  2020-06-01

3.  Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Authors:  Kristofer Wollein Waldetoft; Sam P Brown
Journal:  PLoS Biol       Date:  2017-12-28       Impact factor: 8.029

4.  Simulating Multilevel Dynamics of Antimicrobial Resistance in a Membrane Computing Model.

Authors:  Marcelino Campos; Rafael Capilla; Fernando Naya; Ricardo Futami; Teresa Coque; Andrés Moya; Val Fernandez-Lanza; Rafael Cantón; José M Sempere; Carlos Llorens; Fernando Baquero
Journal:  mBio       Date:  2019-01-29       Impact factor: 7.867

5.  Aggressive or moderate drug therapy for infectious diseases? Trade-offs between different treatment goals at the individual and population levels.

Authors:  Jérémie Scire; Nathanaël Hozé; Hildegard Uecker
Journal:  PLoS Comput Biol       Date:  2019-08-12       Impact factor: 4.475

6.  Antibiotic Killing of Diversely Generated Populations of Nonreplicating Bacteria.

Authors:  Ingrid C McCall; Nilang Shah; Adithi Govindan; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 7.  Antibiotic chemotherapy against heterogeneous pathogen populations in complex host tissues.

Authors:  Dirk Bumann; Joseph Fanous; Jiagui Li; Frédéric Goormaghtigh
Journal:  F1000Res       Date:  2019-10-21

Review 8.  COVID-19 and the gastrointestinal tract: Source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection?

Authors:  Jacopo Troisi; Giorgia Venutolo; Meritxell Pujolassos Tanyà; Matteo Delli Carri; Annamaria Landolfi; Alessio Fasano
Journal:  World J Gastroenterol       Date:  2021-04-14       Impact factor: 5.742

9.  Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.

Authors:  Elsje Pienaar; Jennifer J Linderman; Denise E Kirschner
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

10.  Human antimicrobial peptide, LL-37, induces non-inheritable reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Cathrine Friberg; Jakob Krause Haaber; Martin Vestergaard; Anaëlle Fait; Veronique Perrot; Bruce R Levin; Hanne Ingmer
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.